Showing results (1-10 of 249) with videos related to
Sort By:
Pageof 25
Frontiers in Oncology|January 19, 2016
Bone Tumor Environment as a Potential Therapeutic Target in Ewing SarcomaFrançoise Redini, Dominique HeymannFuture Oncology (London, England)|February 13, 2015
TRAIL-based therapy in pediatric bone tumors: how to overcome resistanceRomain Guiho, Kevin Biteau, Dominique Heymann, et al.Expert Opinion on Pharmacotherapy|January 14, 2011
Mifamurtide for the treatment of nonmetastatic osteosarcomaKosei Ando, Kanji Mori, Nedège Corradini, et al.Drug Discovery Today|June 18, 2010
Proteoglycans on bone tumor developmentCarmen Ruiz Velasco, Sylvia Colliec-Jouault, Françoise Redini, et al.Cancer|November 5, 2005
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing miceBenjamin Ory, Marie-Françoise Heymann, Akira Kamijo, et al.Recent Patents on Anti-Cancer Drug Discovery|November 11, 2008
Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorptionBénédicte Brounais, Carmen Ruiz, Julie Rousseau, et al.International Journal of Oncology|December 6, 2005
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cellsYohann Wittrant, François Lamoureux, Kanji Mori, et al.Oncotarget|May 28, 2015
Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastasesAudrey Lamora, Mathilde Mullard, Jérôme Amiaud, et al.Cancer Biotherapy & Radiopharmaceuticals|January 6, 2012
Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcomaElisabeth Miot-Noirault, François Gouin, Marie-Mélanie Dauplat, et al.Bone|June 6, 2006
OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradationSteeve Kwan Tat, Marc Padrines, Sandrine Theoleyre, et al.Pageof 25